We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 526

Sanofi seeks IPR of Cabilly patent
  • Foley & Lardner LLP
  • USA
  • July 30 2015

On July 27, 2015, Sanofi-aventis U.S. LLC and Regeneron Pharmaceuticals, Inc. filed a petition for Inter Partes Review (IPR) of the “Cabilly II”


USPTO issues July 2015 updated guidance on subject matter eligibility analysis
  • Foley & Lardner LLP
  • USA
  • July 30 2015

On July 30, 2015, the United States Patent and Trademark Office (USPTO) issued updated guidance regarding subject matter eligibility analysis to


Biosimilars can sit out patent dance, but may have to wait out second exclusivity period
  • Foley & Lardner LLP
  • USA
  • July 24 2015

In Amgen v. Sandoz, Fed. Cir., No. 15-1499 (July 21, 2015), a divided panel of the Federal Circuit issued its first decision interpreting the


Federal Circuit finds biosimilar patent dispute resoluation procedures optional
  • Foley & Lardner LLP
  • USA
  • July 21 2015

In Amgen v. Sandoz, a divided panel of the Federal Circuit issued its first decision interpreting the Biologics Price Competition and Innovation Act


Federal Circuit answers questions about covered business method review proceedings
  • Foley & Lardner LLP
  • USA
  • July 21 2015

In Versata Development Group, Inc. v. SAP America, Inc., the Federal Circuit outlined the permitted extent of judicial review of Covered Business


Simultaneous invention as secondary evidence of obviousness
  • Foley & Lardner LLP
  • USA
  • July 21 2015

I do not usually write about non-precedential Federal Circuit decisions, but I could not let the discussion of “simultaneous invention” in Columbia


Federal Circuit finds biosimilar patent dispute resolution procedures optional
  • Foley & Lardner LLP
  • USA
  • July 21 2015

In Amgen v. Sandoz, a divided panel of the Federal Circuit issued its first decision interpreting the Biologics Price Competition and Innovation Act


Contract manufacturing makes Angiomax patents invalid under on sale bar
  • Foley & Lardner LLP
  • USA
  • July 14 2015

In The Medicines Company v. Hospira, Inc., the Federal Circuit held that a transaction with a contract manufacturer gave rise to an on sale bar that


Federal Circuit upholds broadest reasonable interpretation in inter partes review
  • Foley & Lardner LLP
  • USA
  • July 12 2015

A divided Federal Circuit denied the petition for rehearing en banc that would have required the court to revisit its decision in In re Cuozzo Speed


Federal Circuit upholds USPTO post-wyeth Patent Term Adjustment procedures
  • Foley & Lardner LLP
  • USA
  • July 7 2015

In Daiichi Sankyo Co. v. Lee, the Federal Circuit upheld the USPTO's post-Wyeth Patent Term Adjustment (PTA) procedures, and found that the USPTO did